Stay updated with breaking news from Roger Adsett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Insmed (NASDAQ:INSM – Get Free Report) had its price objective upped by analysts at Guggenheim from $50.00 to $52.00 in a research report issued on Tuesday, FlyOnTheWall reports. Guggenheim’s price objective would indicate a potential upside of 94.47% from the stock’s current price. A number of other equities research analysts have also recently commented on […]
Panagora Asset Management Inc. increased its holdings in Insmed Incorporated (NASDAQ:INSM – Free Report) by 8.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 448,581 shares of the biopharmaceutical company’s stock after acquiring an additional 34,862 shares during the quarter. […]
StockNews.com started coverage on shares of Insmed (NASDAQ:INSM – Free Report) in a report published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages also recently issued reports on INSM. HC Wainwright reiterated a buy rating and set a $52.00 price objective on shares of Insmed […]
Pictet Asset Management SA trimmed its holdings in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 1.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 3,930,763 shares of the biopharmaceutical company’s stock after selling 55,786 shares during the period. Pictet Asset Management SA owned approximately 2.88% […]
Morgan Stanley reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a report released on Friday morning, Benzinga reports. Morgan Stanley currently has a $41.00 target price on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on the company. HC Wainwright reissued a buy […]